Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota
PublisherNature Publishing Group
MetadataShow full item record
AbstractClostridium difficile is the leading cause of nosocomial diarrhea and colitis in the industrialized world. Disruption of the protective gut microbiota by antibiotics enables colonization by multidrug-resistant C. difficile, which secrete up to three different protein toxins that are responsible for the gastrointestinal sequelae. Oral agents that inhibit the damage induced by toxins, without altering the gut microbiota, are urgently needed to prevent primary disease and break the cycle of antibiotic-induced disease recurrence. Here, we show that the anthelmintic drug, niclosamide, inhibits the pathogenesis of all three toxins by targeting a host process required for entry into colonocytes by each toxin. In mice infected with an epidemic strain of C. difficile, expressing all three toxins, niclosamide reduced both primary disease and recurrence, without disrupting the diversity or composition of the gut microbiota. Given its excellent safety profile, niclosamide may address an important unmet need in preventing C. difficile primary and recurrent diseases. Copyright 2018, The Author(s).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85058131152&doi=10.1038%2fs41467-018-07705-w&partnerID=40&md5=fb4e200d267435d8df77fe233a783df0; http://hdl.handle.net/10713/9280
- Nonantimicrobial drug targets for Clostridium difficile infections.
- Authors: Darkoh C, Deaton M, DuPont HL
- Issue date: 2017 Sep
- Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
- Authors: Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG
- Issue date: 2016 Nov
- Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
- Authors: Carter GP, Chakravorty A, Pham Nguyen TA, Mileto S, Schreiber F, Li L, Howarth P, Clare S, Cunningham B, Sambol SP, Cheknis A, Figueroa I, Johnson S, Gerding D, Rood JI, Dougan G, Lawley TD, Lyras D
- Issue date: 2015 Jun 2
- A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
- Authors: Gebhart D, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey CJ, Lawley TD, Govoni GR
- Issue date: 2015 Mar 24
- Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
- Authors: Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L
- Issue date: 2018 May